Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2119472 | 1.00 | CHRM2 (0.36) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL2493223 | 0.86 | CHRM2 (0.37) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL2498342 | 0.86 | CHRM2 (0.37) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL2121652 | 0.77 | PPM1D (0.32) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL25347682 | 0.74 | CHRM2 (0.37) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL28735688 | 0.74 | CHRM2 (0.41) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL29519744 | 0.74 | CHRM2 (0.41) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL6488112 | 0.72 | EPHX1 (0.35) | CHRM2CHRM1CHRM3NR1H2RORC | |
| SCHEMBL8990002 | 0.72 | NR1H2 (0.36) | CHRM2CHRM1CHRM3NR1H2RORC | |
| SCHEMBL28626040 | 0.72 | NR1H2 (0.39) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, EIF2AK2, PREP | CHRM2 4758/4885CHRM1 4719/4885CHRM3 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.